MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Qiagen and AstraZeneca Broaden Companion Diagnostic Partnership Beyond Cancer

NextEdge Admin

29 Aug 2024

2 min 0 sec

AstraZeneca,PCR,Diagnostics,Chronic diseases

Qiagen announced an expansion of its companion diagnostic collaboration with AstraZeneca, extending beyond cancer to encompass future therapies for chronic diseases. As part of this agreement, Qiagen will develop and validate a genotyping assay on its QIAstat-Dx platform. This assay will enable specialty care providers to conduct genotyping during routine clinical examinations, potentially helping to determine patient suitability for AstraZeneca's genomically targeted medicines.

Fernando Beils, Senior Vice President and head of Qiagen's molecular diagnostics business area, expressed enthusiasm for the expanded partnership. "We are pleased to extend our collaboration with AstraZeneca into new disease areas using our QIAstat‑Dx system," Beils stated. He highlighted that this marks the development of the first companion diagnostic for chronic diseases based on the QIAstat-Dx platform. "The development of the QIAstat-Dx genotyping assay with AstraZeneca showcases Qiagen's expertise in companion diagnostic development and commercialization, utilizing the most suitable molecular testing platform to meet the unique clinical and commercial needs of patient testing."

The QIAstat-Dx system employs real-time PCR technology, delivering results in approximately an hour. Qiagen also noted that it has master collaboration agreements with over 30 companies to develop and commercialize companion diagnostics, demonstrating its strong position in this critical area of precision medicine.